News Search Results
Sep 03, 2025, 03:00 ET LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression
therapeutics, combining cutting-edge AI design with scalable, cell-free expression technology. About LenioBio LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins
More news about: LenioBio
Sep 02, 2025, 19:30 ET Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Sep 02, 2025, 15:58 ET FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Sep 02, 2025, 12:27 ET Industrial Enzymes Market Size, Trends & Growth | Projected USD 17.77 Billion by 2035 at 7.65% CAGR
biodiesel production, supporting global renewable energy goals.Enzyme Engineering & Precision Fermentation: Advances in biotechnology are leading to highly tailored enzymes with improved efficiency and stability.Expansion in Healthcare Applications: Growing use
More news about: Vantage Market Research
Sep 02, 2025, 10:43 ET Curis to Present at Upcoming Healthcare Conferences in September
Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James
More news about: Curis, Inc.
Sep 02, 2025, 10:01 ET Digital Forensics Market is Projected To Reach US$12.67 Million By 2031; at CAGR Of 11.5% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 02, 2025, 09:30 ET Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
Calif., Sept. 2, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a full data
More news about: Evommune, Inc
Sep 02, 2025, 09:10 ET Wonderfeel's Clinical Brief Gets Published as Its Flagship Formula Earns Wellness From Within Award
Wonderfeel's Director of Research and Development, a medical doctor and clinical pharmacologist with more than 25 years of experience in pharmaceuticals, biotechnology, and medical devices. The observational data, collected through user-reported surveys, point to consistent and wide-ranging benefits:
More news about: Wonderfeel
Sep 02, 2025, 09:10 ET Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
gastrointestinal tumors are flu-like symptoms and neutropenia. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results
More news about: Oncolytics Biotech® Inc.
Sep 02, 2025, 09:05 ET Robles BioCeutics Welcomes Top-Ranked Regenerative Medicine Physician Dr. Navneet Boddu to Advisory Board
Sept. 2, 2025 /PRNewswire/ -- Robles BioCeutics, a regenerative dermatology biotechnology company developing next-generation skincare solutions through stem cell-derived and senolytic technologies, is pleased to welcome Dr. Navneet
More news about: Robles BioCeutics
Sep 02, 2025, 09:01 ET AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology. Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40
More news about: Amgen
Sep 02, 2025, 08:54 ET Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C. Wainwright 27th
More news about: Anixa Biosciences, Inc.
Sep 02, 2025, 08:30 ET Amorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based Therapeutics
causes." About Amorphical Amorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims
More news about: Amorphical
Sep 02, 2025, 08:00 ET Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer
Mass., Sept. 2, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of
More news about: Hemab Therapeutics
Sep 02, 2025, 08:00 ET Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced participation in two upcoming scientific
More news about: Kodiak Sciences Inc.
Sep 02, 2025, 08:00 ET EDETEK Launches BioStat.AI: The Industry's First Unified AI Platform for Clinical Data, Biostatistics, and Programming
solutions company that provides high-quality Artificial Intelligence-powered technology platforms and related clinical services to pharmaceutical, biotechnology, and medical device companies. With a global presence across four continents and serving clinical development globally, EDETEK's commitment to excellence
More news about: EDETEK, Inc.
Sep 02, 2025, 08:00 ET Melodia Therapeutics Appoints Jonathan Talbot as CEO, Sven Zimmermann as Chairman of the Board and Brings Renowned Scientific and Clinical Advisors to Propel Lead Program MLD-151 Towards the Clinic
Amsterdam in September 2025. About Melodia Therapeutics Melodia Therapeutics is a Swiss-based biotechnology company focused on developing oral therapies that target neutrophilic inflammation. Its lead candidate, MLD-151, is a novel DPP1 inhibitor designed
More news about: Melodia Therapeutics AG
Sep 02, 2025, 08:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
Sept. 2, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug
More news about: SystImmune, Inc.
Sep 02, 2025, 08:00 ET ETHZilla Plans to Deploy $100 Million in ETH to EtherFi for Restaking Initiatives
DeFi founders, infrastructure pioneers and other ecosystem heavyweights. The Company, originally formed as an innovative biotechnology company, has also been evolving its business towards software enabled gaming and entertainment. In addition to its ETH treasury strategy
More news about: ETHZilla Corporation
Sep 02, 2025, 07:47 ET Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Sept. 2, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Sep 02, 2025, 07:30 ET Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Sep 02, 2025, 07:22 ET BPC Instruments expands into the textile sector - receives order from a global materials company
instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing
More news about: BPC Instruments AB
Sep 02, 2025, 07:00 ET Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Sep 02, 2025, 06:38 ET Specialty Polymer Market Size to Project USD 179.48 Billion by 2035 | CAGR 6.75% | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 02, 2025, 06:00 ET Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
September 15 to 19, 2025. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.